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Abstract: 
Introduction:  
Renal cell carcinoma (RCC) is an important cause of morbidity and mortality in our 
country. Previously reported data suggest that the overall incidence of RCC continues to 
rise and may be accelerating even faster among younger adult patients. 
Methods:  
Data for analysis included the combined NPCR-SEER USCS public use database and the 
Kentucky Cancer Registry dataset. Incidence rates and trends by age group and location 
were calculated and tested. Clinicopathologic features of disease among Kentucky cases 
were analyzed by age group. Cancer-specific survival (CSS) analysis was performed, 
along with Cox proportional hazards regression to test for association of younger age 
with improved CSS. 
Results:  
Incidence of RCC is higher in KY than in the rest of the country, and the rate is increasing 
faster, especially among younger adults. Annual percent change (APC) for patients in the 
20-39 year-old age group was 8.5% (95% CI 5.9-11.2%), compared to only 4.4% (95% CI 
3.5-5.3%) for the same age group in the rest of the country. APC among older patients in 
KY was 5.4% (95% CI 3.4-7.5%) for ages 40-49 and 1.8% (95% CI 0.8-2.9%) for ages 50+. 
Younger adult patients in KY were significantly more likely to be diagnosed with RCC of 
lower stage, lower grade, and more favorable histologic subtype. Survival curves by age 
group were similar when stratified by disease stage. Cox proportional hazards regression 
analysis revealed hazard ratio (HR) of 0.72 (95% CI 0.47-1.09) for the 19-39 age group 
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and 0.61 (95% CI 0.49-0.76) for the 40-49 age group relative to the 50+ age group, 
adjusted for sex, stage, grade, and subtype. 
Conclusion: 
Young adults in Kentucky are increasingly likely to be diagnosed with RCC. However, 
they tend to have more favorable disease features compared to older adults, and 
possibly improved survival. More work will be needed to determine potential causes 
and implications of accelerating incidence, as well as to guide treatment decisions and 
post-treatment surveillance for these patients.  
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Background: 
An estimated 64,000 patients were diagnosed with kidney cancers—overwhelmingly 
renal cell carcinoma (RCC)—in 2017, and over 14,000 patients died.1 Among new cancer 
diagnoses, kidney cancers are the sixth most common in men and tenth among women 
in the United States, the ninth most common in Europe, and twelfth worldwide.1,2 While 
nationwide incidence of new cancer diagnoses continue to decline overall in our 
country, there is ample epidemiological evidence of a long-term increase in the 
incidence of renal cell carcinoma in the United States and in other developed nations.1,3–
6 Daily clinical experience for many urologists and other providers suggests that an 
increasing proportion of these new RCC diagnoses occur in younger adults relative to 
the more typical RCC patients, who are classically diagnosed in their seventh or eighth 
decades. This anecdotal trend is substantiated by a small number of studies presenting 
data supporting that observation.3,7  
Over the last two decades, the epidemiology of renal cell carcinoma has been 
examined at state, regional, national, and international levels, and several centers have 
reported their experience with young adult patients in particular.8–20 A pivotal study by 
Chow and colleagues in 1999 using SEER data from the 9 geographic areas for the years 
1975 through 1995 suggested that the observed “rapidly rising incidence of renal cell 
carcinoma in the United States” could not be explained merely by the increased use of 
abdominal imaging such as ultrasound, computed tomography (CT) scans, and magnetic 
resonance imaging (MRI) as had been suggested by other authors.20 Since then, a similar 
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increase in incidence has been described in other reviews of large registry data in the US 
and other developed countries.11  
The most comprehensive contemporary review of national-level data in the 
United States was performed by King, et al and published in 2014.3 In their study, they 
used the United States Cancer Statistics (USCS) public use database, which is comprised 
of combined cancer incidence data from the Centers for Disease Control and 
Prevention’s (CDC’s) National Program of Cancer Registries (NPCR) and the National 
Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) Program 
registries, to examine incidence trends over the decade from 2001 to 2010. While they 
emphasize the high annual percent change (APC) in incidence rate seen in the 20-24 
year-old age group over that span, review of their data demonstrates that in actuality all 
patient groups from 20-39 had consistently higher APC (6.3-7.5%) than older (0.9-4.1%) 
and younger (3.9%) age groups.3  
While their findings generally corroborate those of others who have noted an 
overall slowing, or even leveling, of RCC incidence rates, the broader population 
coverage (91.3% of U.S. population) of their cohort makes the observation particularly 
compelling, and the granular incidence rate data for 5-year age categories seems to 
show a clear difference between the rates seen in each of the 20-39 age groups 
compared to the older groups. The APC for the 40-44 (4.1%) and 45-49 (3.2%) age 
groups seem to represent the transition period to the more typical RCC population, with 
all age groups 50 and older showing APC of 2.1% or lower. Despite this more attenuated 
rate increase among the older age groups, they still represent the demographic most 
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likely to be diagnosed with RCC, with incidence peaking in the 65-79 year-old age 
groups, which have incidence rates of 49.2 to 51.2 per 100,000 individuals (age-adjusted 
to 2000 U.S. Standard Population), compared to 13.1 or lower in all the age groups 
younger than 50 (and less than 1 in patients 20-29).3  
The three most well-documented risk factors for renal cell carcinoma are 
smoking, obesity, and hypertension.21 A recent meta-analysis examined 109 case-
control studies and 37 cohort studies and estimated the relative risk (RR) of RCC among 
current smokers to be 1.36 (95% CI 1.19-1.56).22 A meta-analysis of data regarding 
obesity and RCC incidence found that each 5 kg/m2 increase in body mass index (BMI) 
confers a RR of 1.24 for men and 1.34 for women.23 Finally, a meta-analysis published 
last year evaluating the risk of renal cell carcinoma in patients with hypertension 
reported a RR of 1.67 (95% CI 1.46-1.90).24 Whether these risk factors alone account for 
the incidence trends seen in developed countries is unknown, although it has been 
suggested that they are at least partially responsible.3 
Most patients who are ultimately diagnosed with renal cell carcinoma are 
initially found to have a “renal mass” on an abdominal imaging study. Few of these 
patients have a biopsy performed prior to making a treatment decision, usually either 
surgery, ablative therapy, or active surveillance.25,26 As a result, “risk stratification” at 
the time of initial diagnosis is a critical component of counseling and treatment 
decision-making in this setting.25,27 Multiple potential patient- and disease-specific 
features factor into the risk stratification process, and many investigators have 
examined them, including several who have focused on younger adult patients. 
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However, most of the studied cohorts are relatively small and/or span large time 
periods. For example, reports from Cleveland Clinic and Mayo Clinic spanned 20 and 30 
years, respectively, and included just over a hundred patients each.8,9  
A multicenter review of 12 European centers also covered a twenty year period, 
which included only patients treated surgically, and identified nearly 5000 total 
patients.28 Of these, only 288 were 40 years of age or younger and they were noted to 
have lower grade and stage and the time of diagnosis, as well as more favorable 
histologic subtype distribution. Multivariate analysis suggested that younger age was an 
independent positive prognostic factor.28 Other studies have also suggested that 
younger age may be an independent favorable prognostic factor, or that younger 
patients with RCC tend to have more favorable clinicopathologic features, such as stage, 
grade, or histologic subtype.10,16,19 However, still other investigators have reported 
findings suggesting the opposite—that younger adult patients may have less favorable 
histologic features and higher rates of lymph node-positive disease.29,30 As a result, risk 
stratification and treatment recommendations lack the requisite evidence base in these 
patients to allow for informed decision-making. 
Following treatment for RCC, the focus shifts to prognosis and surveillance. 
Ideally, we would be able to identify predictors for long-term cancer-specific and overall 
survival for these young adult patients, but to date there has not been robust literature 
characterizing these outcomes.31 As a result, counseling patients requires relying on the 
data that is currently available—again based on an older population who may not 
necessarily have the same disease. In the absence of good long-term outcome data, we 
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can look at those variables that we believe most importantly contribute to survival, both 
cancer-specific and overall, and try to draw conclusions from that data instead. The 
most important known prognostic factors for patients treated for RCC are tumor grade, 
disease stage, and histologic subtype.27,32,33 To date, there is debate about the role of 
younger age in cancer-specific outcomes in RCC. 
The rising incidence of RCC in the young adult population presents challenges for 
providers as they try to provide evidence-based care to these patients. The majority of 
guidelines and evidence sources are primarily based on the more typical RCC patient 
population consisting of patients over 50 years of age. In the absence of more specific 
guidance, these general treatment and surveillance recommendations and protocols are 
then applied to the younger patients, some of whom will complete both treatment and 
prescribed post-treatment surveillance before they reach even 40 years of age. There is 
basically no literature to guide clinicians for these patients once they have completed 
the protocols, in terms of how to monitor, if at all, for disease recurrence over the 
several remaining decades of life expectancy for many of them.31 
 This challenge is magnified by the recognition that renal cell carcinoma in the 
adolescent population seems to be a different entity than that of the adult population in 
general, and if there is an age or time period at which one transitions to the other, it is 
unknown.34–36 Some authors have designated age less than 40 or 45 as the “young 
adult” population with regard to RCC, but there is no clear scientific basis for either 
cutoff point at this time.10,13,31,32,37 One study evaluating the differing presentations of 
hereditary RCC proposed a genetic testing cutoff age of 46 years, and is likely the most 
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rigorous attempt thus far to identify a specific age under which patients might 
appropriately be considered as a separate group.38 However, at this time there is no 
consensus among clinicians or investigators regarding an age below which patients can 
or should be categorized as “young adult,” as opposed to a more typical RCC population. 
 The purpose of this study is to use high-quality, actively-collected cancer registry 
data to examine the epidemiology of renal cell carcinoma in the young adult population 
in Kentucky (KY) in an effort to better understand the incidence rates and trends, 
clinicopathologic features important to prognosis, and cancer-specific survival for these 
patients relative to the more typical, older adult cohort of RCC patients.  
 
Methods: 
Appropriate institutional review board (IRB) approval was obtained from our institution, 
and data access request for the Kentucky Cancer Registry (KCR) was submitted and 
approved. Request documentation for access to the combined NPCR-SEER USCS public 
use dataset was also submitted and subsequently approved. The Kentucky Cancer 
Registry is the official population-based central cancer registry for the Commonwealth 
of Kentucky and reports its data to both SEER and NPCR. The USCS public use dataset 
includes cancer incidence data from registries covering the entire U.S. population, 
including central cancer registries reporting to NPCR in 45 states and the District of 
Columbia and to SEER in 5 states. These central cancer registries actively collect data for 
all new cancer diagnoses from patient records at various medical facilities and from 
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state vital records, and use uniform data items and codes which conform to the 
standards set by the North American Association of Central Cancer Registries.39  
 Surveillance Research Program, National Cancer Institute SEER*Stat software 
version 8.3.5 was used to access and analyze the USCS data for the years 2001-2014, 
including only cases that meet USCS standard. Cases were further selected based on 
International Classification of Diseases for Oncology, Third Edition (ICD-O-3) site recode 
64.9, restricted to histology codes 8050/3, 8140/3, 8255/3, 8260/3, 8310/3, 8312/3, 
8316/3, 8317/3, 8318/3, and 8320/3. Average annual rates per 100,000 population by 
age group (20-39, 40-49, and 50+) and registry location (Kentucky vs not) for the time 
period 2001-2014 were analyzed and compared. Rate denominators are based on 
annual county population estimates produced by the U.S. Census Bureau, in 
collaboration with CDC and supported by NCI, and are age-adjusted by the direct 
method to the 2000 U.S. standard population.40 Percent change over the course of the 
study period was calculated using a two-year average for each end point. Annual 
percent change (APC) was used to quantify the change in rates over the course of the 
study period and was calculated using least squares regression. Two-sided t-test was 
used to test if the APC was different from zero.  
 The Kentucky Cancer Registry data for patients with topo code C64.9 were 
examined for the years 1995-2015. All KCR analyses were performed using age groups 
19-39, 40-49, and 50+. Individual histology codes were grouped into subtypes as 
follows: Renal cell carcinoma (no subtype specified—NOS), 8312; clear cell subtype, 
8005 and 8310; papillary subtype, 8050 and 8260; chromophobe subtype, 8317; and 
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remainder of codes were categorized as “other.” Race was categorized as “White,” 
“Black,” and “Other/Unknown.” The derived “Best Stage Group” variable was used to 
create the following stage groups for analysis and is based on the American Joint 
Committee on Cancer (AJCC), 6th edition stage groups: numeric codes <30: “Stage I”; 
codes 30-49: “Stage II”; codes 50-69: “Stage III”; codes 70-74: “Stage IV”; and codes 88 
and 99: “N/A or Unknown.” Follow-up duration was determined using the date of 
diagnosis and the date of last contact or death, rounded to the nearest month. Cause of 
death codes “C64.9” and “189” were considered RCC disease-specific cause of death. 
 Differences in distribution of characteristics across all age groups were tested for 
using the chi-square test for independence for sex, race, grade, stage, and histologic 
subtype. Then the distribution of these variables for each specific young adult patient 
group was tested for differences against the older adult group (age 50+) using Pearson 
chi-square test.  
 Cancer-specific survival analysis was performed for the same age groups. Kaplan-
Meier cancer-specific survival curves were created by age group, then by age group 
stratified by stage. Log-rank test was performed to test for equality of cancer-specific 
survival distributions for the three different levels of age group. Cox proportional 
hazards regression was performed for those patients with known sex, histologic subtype 
(clear cell, papillary, chromophobe, or other), grade, and stage.   
 Data from the SEER database was analyzed using SEER*Stat software version 
8.3.5. The data from the Kentucky Cancer Registry was analyzed using SPSS v24 (IBM). 
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Results: 
The USCS dataset included 12,059 cases in Kentucky and 678,042 cases outside 
Kentucky that met all selection criteria, while the KCR dataset included 13,564 patients. 
Incidence rate by year for each age group by KY and non-KY location are shown in Figure 
1. Over the course of the study period, the overall percent change for the 20-39 age 
group in KY was 163.1%, compared to only 68.5% for the non-KY cases. The percent 
change for the 40-49 age group was also higher for KY, 88.6%, compared to 44.9% for 
non-KY cases, while percent change for the 50+ age group was similar for both locations 
(23.3% vs 20.8%). The annual percent change (APC) was significantly higher for the 
youngest patients in KY compared to the rest of the country, 8.5% (95% CI 5.9-11.2%) 
per year, compared to only 4.4% (95% CI 3.5-5.3%) per year (p<0.05), as seen in Figure 
2. The APC for the 40-49 and 50+ age groups were also higher for KY cases, but the 
confidence levels overlapped for these groups.       
 Age group characteristics for the KCR cases are shown in Table 1. About 2000 
(16.5%) of the patients were under the age of 50 at the time of diagnosis, including over 
600 (4.5%) who were less than 40. Median follow-up for the entire cohort was about 
three and a half years, while the median follow-up among the young adult groups was 
nearly five years. Race distribution was similar across the three age groups, but the 
younger groups had a significantly higher proportion of female cases, nearly 50%, 
compared to a more traditional 60% male-40% female distribution among the older age 
groups (p<0.001).  
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 Pathologic characteristics by age group are described in Table 2. Overall, the 
younger patients had statistically different and more favorable disease distribution. 
Over 70% of the 20-39 age group had Stage 1 disease, compared to less than half of the 
50+ age group, and only 13% of the youngest group presented with advanced Stage 3 or 
4 cancer, while over 30% of the oldest group did (p<0.001). Younger patients had 
similarly lower rates of high grade disease compared to more traditional RCC patients, 
59.1% vs 41.2%, although substantially more patients in the 50+ group had unknown 
grade—34.6% vs 18.1%. Analysis of histologic subtype was also hampered by many 
cases having either “other” (10.8%) or “non-specific” (35.9%) subtype. However, 
patients in the younger groups do seem to be somewhat more likely to be diagnosed 
with the (generally) more indolent chromophobe subtype.    
 Kaplan-Meier curves for cancer-specific survival by age group are seen in Figure 
3. Log-rank test for difference between older and younger age groups revealed p<0.001. 
However, Kaplan-Meier curves for cancer-specific survival by age group stratified by 
stage (Figure 4) show similar curves across all three age groups out to 10 years. Results 
of Cox proportional hazards regression are shown in Table 3. Results suggest that 
younger age may be an independent favorable prognostic factor, with hazard ratio (HR) 
of 0.72 (95% CI 0.47-1.09) for the 19-39 age group and 0.61 (95% CI 0.49-0.76) for the 
40-49 age group relative to the 50+ age group when accounting for sex, stage, grade, 
and subtype.  
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Discussion: 
Classically, renal cell carcinoma has been considered a disease of older adults, and the 
preponderance of clinical data and guidelines are based on studies of these patients. 
However, as our data demonstrate, and other studies have suggested, the proportion of 
young adult patients diagnosed has been steadily increasing, both nationally and within 
Kentucky. As we encounter more young adult patients with RCC, the clinician is faced 
with the question of whether the accumulated literature regarding the disease process 
in older adults also applies to these patients for purposes of risk stratification, treatment 
counseling and decision-making, and post-treatment surveillance. 
 A few other investigators have described the higher APC among younger adults 
previously, although this is the first to include national data beyond 2010.3,13 
Interestingly, we also see that this trend is even more pronounced in Kentucky. There 
are several known risk factors that have been identified for RCC among adults—
smoking, obesity, and hypertension the most commonly described—and these may be 
contributing to the increased incidence and rate of growth in Kentucky.5,11,41 However, 
whether these risk factors alone are able to explain the incidence trends nationwide or 
in Kentucky is unknown at this time. 
 It also remains to be seen whether the RCC incidence trends we have seen 
nationwide and within KY will continue their current course. These patients already 
comprise a larger proportion of RCC patients than ever before, and that proportion may 
continue to grow. Several investigators have noted an apparent plateau in overall RCC 
incidence, while the younger group rates continue to accelerate.3,12,13 Data about the 
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behavior of the disease in these patients will be increasingly important for providers as 
they guide the patients through treatment choices, treatment itself, and the post-
treatment surveillance process.42 Current guidelines from the American Urological 
Association and European Urological Association do not give any guidance for 
surveillance of these patients beyond the generic prescription for all patients, despite 
the fact that they may have decades more survival time ahead of them than the typical 
patient.25,26 
 Our analysis sheds some light on the question of disease behavior in the young 
adult population. Young adults in Kentucky are more likely to be diagnosed with renal 
cell carcinoma with favorable pathologic features—grade, stage, and histologic 
subtype—than their older counterparts. The stage difference, at least, could be a 
function of earlier diagnosis, but the grade and subtype are more likely to be related to 
differences in tumor biology. Our data do not corroborate other studies that have 
suggested more aggressive disease in these patients, but rather are more consistent 
with those who have identified more favorable features.10,16,29,30 
 These more favorable pathologic features are important for risk stratification 
and treatment planning. These patients are more likely to be candidates for nephron-
sparing surgery, and with data demonstrating the long-term mortality associated with 
chronic kidney disease, such approaches might be especially important among young 
adult patients with their prolonged life expectancy relative to older patients.43  
 The cancer-specific survival data for these younger patient age groups are 
important for clinicians who are treating and counseling patients who present with 
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possible RCC or are diagnosed and treated for it. In particular, the survival curves and 
regression analysis suggest that prognosis for these patients is at least as good as their 
older counterparts, and potentially even better. Hazard ratio estimate for the youngest 
group was 0.72, but with a wide confidence interval that included 1, likely due to the 
relatively low number of these patients in the model. The HR for the 40-49 group was 
lower still, at 0.61, with a much narrower 95% CI of 0.49-0.76. As the most important 
known prognostic factors (grade, stage, and histology) are included in the model, it is 
suggested that there is truly a cancer-specific survival advantage for these patients that 
is independent of the known pathologic features, as has been seen in studies of other 
populations.16,19,37  
 As with all registry-based studies, there are potential weaknesses or concerns 
about interpreting the results. We are subject to the quality of the data collection, 
which is inevitably imperfect. A meaningful proportion of the patients had incomplete 
and/or non-specific data regarding stage and grade, for example. Generalizability is 
sometimes an issue when dealing with registry data; however, by using the combined 
NPCR-SEER data for the incidence analyses, we hopefully have captured a much broader 
population than most similar studies. For the Kentucky data, all cases should be 
collected, but it is possible that some were missed or were never diagnosed based on 
the limited access to care of some KY patients. Longer follow-up data would have been 
ideal for the cancer-specific survival analyses. Finally, residual confounding is certainly a 
concern as there is important data about risk factors that we do not have, as well as 
other potential unknown variables of importance.44  
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 Moving forward, there is more to be done as we try to better understand the 
young adult RCC patient cohort. We need to determine how to follow these patients 
long-term. Registry data may provide those answers someday, but to date there is no 
specific guidance for surveillance for these patients. At the individual patient level, 
better molecular testing and analysis of these tumors may provide insights into the basic 
tumor biology underlying the clinical manifestations and potentially give clues as to 
better targeted or personalized therapies for advanced disease. Finally, the American 
Urological Association (AUA) released specific guidelines in 2017 about genetic testing 
for patients under the age of 45 who are diagnosed with RCC.25 As more patients are 
tested and genetic data accumulates, we may find guidance for how to treat and follow 
these patients based on underlying genetic determinants and risk factors for recurrence. 
 
Conclusion: 
 Young adults in Kentucky are increasingly likely to be diagnosed with RCC. 
However, they tend to have more favorable disease features compared to older adults, 
and likely improved cancer-specific survival as well. More work will be needed to 
determine potential causes and implications of the accelerating incidence, as well as to 
guide treatment decisions and post-treatment surveillance for these patients.  
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Figure 1: Incidence rates by year and age group for patients in KY vs the rest of the 
United States (“Non-KY”). USCS data, 2001-2014 
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Figure 2: Annual percent change and confidence intervals by age group, KY vs “Non-KY” 
for the years 2001-2014 
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Table 1: Basic demographics by age group; KCR 1995-2015 
    
19-39 40-49 50+ Total 
N= 614 
(4.5%) 
N= 1620 
(11.9%) 
N=11,330 
(83.5%) N=13.564 
Sex Male 319 (52.0%)* 1016 (62.7%) 6892 (60.8%) 8227 (60.7%) 
  Female 295 (48.0%)* 604 (37.3%) 4438 (39.2%) 5337 (39.3%) 
Race White 550 (89.6%) 1488 (91.9%) 10491 (92.6%) 
12529 
(92.4%) 
  Black 55 (9.0%) 120 (7.4%) 798 (7.0%) 973 (7.2%) 
  Other/Unk 9 (1.5%) 12 (0.7%) 41 (0.4%) 62 (0.5%) 
Follow-up months 58 (24, 93) 57 (21, 104) 39 (11, 85) 42 (13, 88) 
*p<0.001 for difference relative to age 50+ 
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Table 2: Pathologic characteristics by age group; KCR 1995-2015 
    19-39 40-49 50+ Total 
Histology RCC NOS 139 (22.6%) 511 (31.5%) 4216 (37.2%) 4866 (35.9%) 
  Clear cell 339 (55.2%) 808 (49.9%) 4638 (40.9%) 5785 (42.6%) 
  Papillary 48 (7.8%) 121 (7.5%) 960 (8.5%) 1129 (8.3%) 
  Chromophobe 37 (6.0%) 44 (2.7%) 241 (2.1%) 322 (2.4%) 
  Other 51 (8.3%) 136 (8.4%) 1275 (11.3%) 1462 (10.8%) 
  p<0.001* p<0.001* Reference  
Grade Low 363 (59.1%) 867 (53.5%) 4673 (41.2%) 5903 (43.5%) 
  High 140 (22.8%) 413 (25.5%) 2738 (24.2%) 3291 (24.3%) 
  Unknown 111 (18.1%) 340 (21.0%) 3919 (34.6%) 4370 (32.2%) 
  p<0.001* p<0.001* Reference  
Stage I 440 (71.7%) 934 (57.7%) 5576 (49.2%) 6950 (51.2%) 
  II 62 (10.1%) 210 (13.0%) 1159 (10.2%) 1431 (10.5%) 
  III 41 (6.7%) 179 (11.0%) 1479 (13.1%) 1699 (12.5%) 
  IV 40 (6.5%) 209 (12.9%) 1946 (17.2%) 2195 (16.2%) 
  Unknown 31 (5.0%) 88 (5.4%) 1170 (10.3%) 1289 (9.5%) 
  p<0.001* p<0.001* Reference  
*Chi square test for difference in distribution relative to reference group – age 50+
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Figure 3: Kaplan-Meier curve for CSS to 15 years by age group. 
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Figure 4: CSS by age group, stratified by stage at diagnosis
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Table 3: Cox proportional hazards regression 
 Hazard ratio 95% CI 
Lower 
95% CI 
Upper p 
Age groups     
50+ Reference   <0.001 
19-39  0.72 .474 1.090 .120 
40-49 0.61 .490 .757 <0.001 
Female vs Male 0.91 .790 1.045 .179 
Stage     
Stage 1 Reference   <0.001 
Stage 2 3.2 2.444 4.100 <0.001 
Stage 3 6.1 4.962 7.484 <0.001 
Stage 4 31.1 25.438 38.025 <0.001 
Grade     
High vs Low 1.8 1.521 2.059 <0.001 
Subtype     
Clear cell  Reference   <0.001 
Papillary 0.82 .641 1.060 .132 
Chromophobe 0.54 .290 1.015 .056 
Other 1.8 1.557 2.148 <0.001 
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